Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Tuesday, Oct 24, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Tucatinib is a tyrosine kinase inhibitor (TKI) that only blocks HER2, sparing patients from some of the adverse effects that come with the neratinib (Nerlynx) and lapatinib (Tykerb). This TKI easily crosses the blood-brain barrier, says Hamilton, so it works well in patients with brain metastases.

Currently, tucatinib is being evaluated in randomized trial with capecitabine and trastuzumab (Herceptin) at Sarah Cannon Research Institute.
 
SELECTED
LANGUAGE


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Tucatinib is a tyrosine kinase inhibitor (TKI) that only blocks HER2, sparing patients from some of the adverse effects that come with the neratinib (Nerlynx) and lapatinib (Tykerb). This TKI easily crosses the blood-brain barrier, says Hamilton, so it works well in patients with brain metastases.

Currently, tucatinib is being evaluated in randomized trial with capecitabine and trastuzumab (Herceptin) at Sarah Cannon Research Institute.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x